Patent application number | Description | Published |
20100208177 | LAMINATED OPTICAL FILM, LIQUID CRYSTAL PANEL, AND LIQUID CRYSTAL DISPLAY APPARATUS - The present invention provides a laminated optical film capable of contributing to thinning of each of a liquid crystal panel and a liquid crystal display apparatus and of simplifying its manufacturing steps, and a method of manufacturing the laminated optical film. The laminated optical film is used in a liquid crystal display apparatus and arranged on a viewer side of a liquid crystal cell. The laminated optical film includes: a polarizer; and a retardation layer which is arranged on one side of the polarizer, has a refractive index ellipsoid showing a relationship of nx>ny=nz, and has an in-plane retardation value Re[590] of 90 to 190 nm. An angle formed between an absorption axis of the polarizer and a slow axis of the retardation layer is 5 to 85°. The retardation layer is formed of a liquid crystal material, and the retardation layer is arranged to be closer to the viewer side than the polarizer is. | 08-19-2010 |
20140220055 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION - The present invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject. | 08-07-2014 |
20140220056 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION - Disclosed is a vaccine composition for transdermal administration to induce cellular immunity, comprising an antigen, wherein Th1 cell ratio in a model animal for immunological evaluation that received the composition is 10% or more. | 08-07-2014 |
20140220057 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION - The present invention provides a cancer vaccine composition for transdermal administration for cellular immunity induction, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a pharmacologically acceptable acid as a first cellular immunity induction promoter, or a pharmacologically acceptable salt thereof. | 08-07-2014 |
20140220058 | VACCINE COMPOSITION FOR TRANSDERMAL OR MUCOSAL ADMINISTRATION - The invention provides a vaccine composition for transdermal or transmucosal administration for inducing cellular immunity, comprising (i) an antigen; and (ii) a pharmacologically acceptable acid or a pharmacologically acceptable salt thereof as a first cellular immunity induction promoter. | 08-07-2014 |
20140220059 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION - The present invention provides a cancer vaccine composition for mucosal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject. | 08-07-2014 |
20140220063 | VACCINE COMPOSITION - The invention provides a vaccine composition containing an antigen for inducing cellular immunity, comprising at least one first cellular immunity induction promoter. | 08-07-2014 |
20140220079 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION - The present invention provides a cancer vaccine composition for mucosal administration comprising (i) a HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide; and (ii) a first cellular immunity induction promoter. | 08-07-2014 |
20140220100 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION - The invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity comprising (i) HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide; and (ii) a first cellular immunity induction promoter. | 08-07-2014 |
20140220105 | TAPE PREPARATION OF WT1 PEPTIDE CANCER VACCINE FOR TRANSDERMAL ADMINISTRATION - The present invention provides a cancer vaccine tape preparation for inducing cellular immunity, comprising:
| 08-07-2014 |
20140234377 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION - The present invention provides a vaccine composition which comprises a cellular immunity induction promoter universally usable against various antigens in cellular immunity induction by mucosal administration of the antigen and exerts a high cellular immunity inducing effect by mucosal administration. The present invention provides a vaccine composition for mucosal administration to induce cellular immunity, comprising: (i) an antigen; and (ii) one or more cellular immunity induction promoters selected from the group consisting of a TLR ligand, a cyclic dinucleotide, a helper peptide and an immunomodulatory small molecule drug. | 08-21-2014 |